VU 0365114 is primarily used in neuroscience research as a positive allosteric modulator (PAM) of the metabotropic glutamate receptor subtype 5 (mGluR5). It enhances the receptor's response to glutamate, making it a valuable tool for studying the role of mGluR5 in various neurological and psychiatric conditions. Researchers utilize this compound to investigate its potential therapeutic effects in disorders such as schizophrenia, anxiety, and Fragile X syndrome. By modulating mGluR5 activity, VU 0365114 helps elucidate the receptor's involvement in synaptic plasticity, learning, and memory processes. Its application in preclinical studies aids in the development of novel treatments targeting glutamate signaling pathways.